{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:08:45Z","timestamp":1786118925041,"version":"build-2736575974"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","license":[{"start":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:00:00Z","timestamp":1773964800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,3,20]]},"abstract":"<jats:p>Immunoglobulin-G4-related disease (IgG4-RD) is a rare recurring fibroinflammatory autoimmune condition that can affect multiple organs. Although it is gaining recognition, few studies have assessed the clinical and economic burden of this disease. This study aimed to characterize patients with IgG4-RD in the United States and describe healthcare resource utilization (HRU) and costs before and after diagnosis. This retrospective cohort study used a validated algorithm to identify commercially insured adult patients with IgG4-RD from health plan claims data obtained from the IQVIA PharMetrics Plus database (January 1, 2011, to June 30, 2022). The index date was defined as the date of the first observed IgG4-RD-related diagnosis. The baseline and study periods were defined as the 12 months before and after diagnosis, respectively. Demographic characteristics were reported on the index date. Clinical characteristics, IgG4-RD-related treatments, and all-cause HRU and healthcare costs (2022 US dollars, payer\u2019s perspective) were reported during the baseline and study periods. A total of 295 patients with IgG4-RD were included in the study. Comorbid burden was substantial, with hypertension (31.5%), hyperlipidemia (22.4%), and type 2 diabetes (17.3%) being the most common comorbidities after diagnosis. Most patients received IgG4-RD-related treatment before (60.3%) and after (87.8%) diagnosis, with prednisone being the most common (71.5% after diagnosis). Pancreatic and biliary involvement each occurred in nearly a third of patients. Annual HRU was high before (mean of 30.4 outpatient [OP] visits; 22.7% with \u22651 inpatient [IP] admission, lasting a mean of 9.0 days) and after diagnosis (mean of 40.7 OP visits; 35.3% with \u22651 IP admission, lasting a mean of 10.6 days). Mean annual healthcare costs were 1.5 times higher after diagnosis ($69,753) than before diagnosis ($45,844), predominantly driven by increased OP and IP costs. Patients with IgG4-RD had a substantial clinical and economic burden, including high rates of glucocorticoid use, HRU, and healthcare costs both before and after diagnosis. This may suggest a need for earlier detection and improved management of this complex condition. This study provides important insights into the high clinical and economic burden observed in IgG4-RD. Future studies are warranted to gain a deeper understanding of the possible impact of management strategies on patient outcomes.<\/jats:p>","DOI":"10.1097\/md.0000000000048098","type":"journal-article","created":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T20:01:48Z","timestamp":1774036908000},"page":"e48098","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Real-world clinical and economic burden of immunoglobulin-G4-related disease in the United States: A retrospective claims-based analysis"],"prefix":"10.1097","volume":"105","author":[{"given":"Zachary S.","family":"Wallace","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Allergy, and Immunology, Rheumatology and Allergy Clinical Epidemiology Research Center, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9099-0975","authenticated-orcid":false,"given":"Jenny Y.","family":"Park","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2832-5355","authenticated-orcid":false,"given":"Elizabeth","family":"Serra","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Gagnon-Sanschagrin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Gu\u00e9rin","sequence":"additional","affiliation":[{"name":"Analysis Group, Inc., Montr\u00e9al, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina R.","family":"Patterson","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haridarshan","family":"Patel","sequence":"additional","affiliation":[{"name":"Amgen Inc., Thousand Oaks, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikesh K.","family":"Singh","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Johns Hopkins Medical Institutions, The John Hopkins Hospital, Baltimore, MD."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260422","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2147\/TCRM.S99985","article-title":"IgG4-related disease: current challenges and future prospects.","volume":"12","author":"Lang","year":"2016","journal-title":"Ther Clin Risk Manag"},{"key":"R2-20260422","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1136\/ard-2023-223950","article-title":"Incidence, prevalence and mortality of IgG4-related disease in the USA: a claims-based analysis of commercially insured adults.","volume":"82","author":"Wallace","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"R3-20260422","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/BOR.0000000000000133","article-title":"An update on IgG4-related disease.","volume":"27","author":"Wallace","year":"2015","journal-title":"Curr Opin Rheumatol"},{"key":"R4-20260422","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1136\/annrheumdis-2019-216561","article-title":"The 2019 American College of Rheumatology\/European League Against Rheumatism classification criteria for IgG4-related disease.","volume":"79","author":"Wallace","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R5-20260422","first-page":"19","article-title":"Diagnosis and treatment of IgG4-related disease.","volume":"401","author":"Kamisawa","year":"2017","journal-title":"Curr Top Microbiol Immunol"},{"key":"R6-20260422","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1111\/1756-185X.12586","article-title":"IgG4-related disease.","volume":"19","author":"Kubo","year":"2016","journal-title":"Int J Rheum Dis"},{"key":"R7-20260422","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.anl.2023.10.006","article-title":"New insights into chronic rhinosinusitis associated with IgG4-related disease.","volume":"51","author":"Takano","year":"2023","journal-title":"Auris Nasus Larynx"},{"key":"R8-20260422","first-page":"22","article-title":"IgG4-related disease: imitating a great imitator.","volume":"74","author":"Fenderson","year":"2015","journal-title":"Hawaii J Med Public Health"},{"key":"R9-20260422","first-page":"e45044","article-title":"Therapeutic uses of rituximab and clinical features in immunoglobulin G4-related disease: a systematic review.","volume":"15","author":"Patel","year":"2023","journal-title":"Cureus"},{"key":"R10-20260422","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.3390\/diagnostics15161990","article-title":"Endoscopic diagnostics for IgG4-related pancreatobiliary diseases: current modalities and clinical perspectives.","volume":"15","author":"Naitoh","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"R11-20260422","doi-asserted-by":"crossref","first-page":"m1067","DOI":"10.1136\/bmj.m1067","article-title":"Advances in the diagnosis and management of IgG4 related disease.","volume":"369","author":"Lanzillotta","year":"2020","journal-title":"BMJ"},{"key":"R12-20260422","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1136\/gutjnl-2012-303617","article-title":"Long-term outcomes of autoimmune pancreatitis: a multicentre, international analysis.","volume":"62","author":"Hart","year":"2013","journal-title":"Gut"},{"key":"R13-20260422","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.pan.2018.09.003","article-title":"Diagnosis, treatment and long-term outcome of autoimmune pancreatitis in Sweden.","volume":"18","author":"Vujasinovic","year":"2018","journal-title":"Pancreatology"},{"key":"R14-20260422","doi-asserted-by":"crossref","first-page":"e001375","DOI":"10.1136\/bmjgast-2024-001375","article-title":"Optimising the indications for biliary stent placement during endoscopic retrograde cholangiopancreatography: a quality improvement initiative to enhance patient care and reduce healthcare resource utilisation.","volume":"11","author":"Alhaidari","year":"2024","journal-title":"BMJ Open Gastroenterol"},{"key":"R15-20260422","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s40744-025-00763-9","article-title":"Burden of glucocorticoid use and risk of toxicities among patients with immunoglobulin-G4-related disease: a retrospective US-based claims study.","volume":"12","author":"Wallace","year":"2025","journal-title":"Rheumatol Ther"},{"key":"R16-20260422","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1007\/s10875-016-0331-0","article-title":"\u201cHow I manage\u201d IgG4-related disease.","volume":"36","author":"Della-Torre","year":"2016","journal-title":"J Clin Immunol"},{"key":"R17-20260422","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/rheumatology\/kev438","article-title":"Predictors of disease relapse in IgG4-related disease following rituximab.","volume":"55","author":"Wallace","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"R18-20260422","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1056\/NEJMoa2409712","article-title":"Inebilizumab for treatment of IgG4-related disease.","volume":"392","author":"Stone","year":"2025","journal-title":"N Engl J Med"},{"key":"R19-20260422","doi-asserted-by":"crossref","first-page":"rkae020","DOI":"10.1093\/rap\/rkae020","article-title":"Current and future advances in practice: IgG4-related disease.","volume":"8","author":"Wallace","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"R20-20260422","doi-asserted-by":"crossref","first-page":"152253","DOI":"10.1016\/j.semarthrit.2023.152253","article-title":"Assessment of patient-reported symptoms and distress in IgG4-related disease (IgG4-RD): development, clinical validation, and content validation of the IgG4-RD symptom severity index.","volume":"63","author":"Wallace","year":"2023","journal-title":"Semin Arthritis Rheum"},{"key":"R21-20260422","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1093\/rheumatology\/keae230","article-title":"The clinical outcomes and healthcare resource utilization in IgG4-related disease: a claims-based analysis of commercially insured adults in the United States.","volume":"63","author":"Wallace","year":"2024","journal-title":"Rheumatology (Oxford)"},{"key":"R22-20260422","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/acr2.11405","article-title":"Derivation and validation of algorithms to identify patients with immunoglobulin-G4-related disease using administrative claims data.","volume":"4","author":"Wallace","year":"2022","journal-title":"ACR Open Rheumatol"},{"key":"R23-20260422","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"R25-20260422","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1080\/1744666X.2017.1354698","article-title":"Diagnostic and treatment workup for IgG4-related disease.","volume":"13","author":"Abraham","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"R26-20260422","doi-asserted-by":"crossref","first-page":"rkz014","DOI":"10.1093\/rap\/rkz014","article-title":"Retrospective single-centre analysis of IgG4-related disease patient population and treatment outcomes between 2007 and 2017.","volume":"3","author":"Lee","year":"2019","journal-title":"Rheumatol Adv Pract"},{"key":"R27-20260422","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1002\/art.39205","article-title":"IgG4-related disease: clinical and laboratory features in one hundred twenty-five patients.","volume":"67","author":"Wallace","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 9","key":"R28-20260422","first-page":"1425","article-title":"The epidemiology, clinical outcomes, and healthcare resource utilization of IgG4-related disease among commercially insured people in the United States [abstract].","volume":"74","author":"Wallace","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R29-20260422","doi-asserted-by":"crossref","first-page":"e000503","DOI":"10.1136\/lupus-2021-000503","article-title":"Disease and economic burden increase with systemic lupus erythematosus severity 1 year before and after diagnosis: a real-world cohort study, United States, 2004\u20132015.","volume":"8","author":"Jiang","year":"2021","journal-title":"Lupus Sci Med"},{"key":"R30-20260422","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3899\/jrheum.150479","article-title":"Clinical and economic burden of antineutrophil cytoplasmic antibody-associated vasculitis in the United States.","volume":"42","author":"Raimundo","year":"2015","journal-title":"J Rheumatol"},{"key":"R31-20260422","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1007\/s12325-021-01730-w","article-title":"Healthcare costs of not achieving remission in patients with rheumatoid arthritis in the United States: a retrospective cohort study.","volume":"38","author":"Bergman","year":"2021","journal-title":"Adv Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048098","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:57:01Z","timestamp":1786035421000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,20]]},"references-count":30,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048098","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,20]]},"assertion":[{"value":"2025-06-16","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-27","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}